Kintara Therapeutics Inc. (KTRA)
0.22
-0.01 (-4.31%)
At close: Oct 17, 2024, 8:00 PM
-4.31% (1D)
| Bid | n/a |
| Market Cap | 11.99M |
| Revenue (ttm) | 76K |
| Net Income (ttm) | -8.5M |
| EPS (ttm) | -11.2 |
| PE Ratio (ttm) | -0.019232142857142857 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 3,552,720 |
| Avg. Volume (20D) | 83,392 |
| Open | 0.24 |
| Previous Close | 0.23 |
| Day's Range | 0.20 - 0.24 |
| 52-Week Range | 0.20 - 26.21 |
| Beta | 0.81 |
About KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intri...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 22, 2013
Employees 1
Stock Exchange NASDAQ
Ticker Symbol KTRA
Website https://www.kintara.com
